Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2019-07-21 Capital/Financing Update
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
New Strategy To Deliver Therapies For Global Pain Market 3 pages 139.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 22 July 2019, providing a strategic update on Regeneus Ltd's focus on commercializing regenerative therapies, particularly Progenza for osteoarthritis. It discusses the company's revised strategy, clinical trial progress, partnerships, and market outlook. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The content is a corporate update on strategy and business direction rather than a formal financial report or regulatory filing. Therefore, it fits best as a Capital/Financing Update (CAP) since it discusses strategic priorities, commercialisation plans, and capital redeployment to support these initiatives.
2019-07-21 English
Appendix 3Z - Final Director's Interest Notice 4 pages 194.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities holdings and interests of directors who have ceased to be directors, including shareholdings and options. This type of document is a formal notification of personal share transactions or holdings by company directors. It does not contain financial statements, management discussion, or other report content. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a report publication notice but a detailed director interest notice.
2019-05-01 English
Appendix 3X - Initial Director's Interest Notice 4 pages 192.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the initial interests of newly appointed directors in securities and contracts, with no financial statements or company performance data. The content is focused on disclosure of directors' personal shareholdings and interests, which aligns with insider trading or director dealings disclosures. The document length is 4313 characters, which is relatively short and contains no financial report data. Therefore, it fits the category of Director's Dealing (DIRS) filings, which report personal share transactions or interests of company directors and executives.
2019-05-01 English
Regeneus Appoints International Directors for Global Growth 3 pages 87.7KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 29 April 2019 regarding the appointment of new board members and the stepping down of existing directors. It details changes in the company's board of directors and senior management, including the appointment of two new independent non-executive directors and the stepping down of two others, as well as the appointment of a new non-executive chairman. There is no financial data, earnings information, or report publication mentioned. The content focuses solely on board and management changes, which fits the category of Board/Management Information (MANG). The document length is 8316 characters, which is sufficient for a detailed announcement but does not contain financial statements or other report types. Therefore, the correct classification is MANG with high confidence.
2019-04-28 English
Appendix 4C - Quarterly 6 pages 451.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly results for the period ended 31 March 2019' and includes detailed financial data such as cash flow statements, operating cash outflows, financing activities, and cash positions for the quarter and year to date. It references Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rule 4.7B. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). It is not merely an announcement or a certification but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-04-10 English
Directors Provide $2.5M Loan to Extend Funding Runway 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 28 February 2019 regarding a $2.5 million loan provided by the company's directors to extend the funding runway. It discusses loan funding, terms, and the purpose of the funds but does not contain financial statements or detailed financial results. The document is relatively short (1940 characters) and is an announcement of a financing event rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-02-27 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.